Tag:
Afrezza
Latest Headlines
Latest Headlines
MannKind shares jump on $370M debt financing plan
After the FDA gave its okay to the design of late-stage trials for the firm's lead inhaled insulin therapy, MannKind ( $MNKD ) has rolled out a $370 million debt-funding plan today to stock its war
MannKind rallies on FDA nod for inhaled insulin trials
The forecast for inhaled insulin--at least for Mannkind--just got a little sunnier. And with the firm's ( $MKND ) stock up more than 20% early this morning, investors appear to be pumped about the drug
MannKind shares slide as new Afrezza Ph3 timeline lengthens
The top execs at MannKind ( $MKND ) sat down yesterday afternoon to review the latest developments on their troubled Afrezza development program and watched as their share price took another hit as
MannKind job cuts hit CT site after FDA rejects inhaled insulin
MannKind's ($MNKD) workforce is feeling the effects of the FDA declining to approve their employer's inhaled insulin therapy Afrezza last month. The Valencia, CA-based company is laying off 131
MannKind axes 179 workers, circles wagons around Afrezza
With its troubled inhaled insulin program stymied at the FDA , MannKind ($MNKD) announced Thursday evening that it will axe 41 percent of its workforce--179 employees--as it circles its remaining
Will Mann be forced to bail out MannKind one more time?
Still reeling from the FDA's second rejection of its inhaled insulin program, MannKind ( $MNKD ) executives are telling the Los Angeles Business Journal that they are redesigning two studies of Afrezza
MannKind slammed with FDA demand for new Afrezza trials
Alfred Mann's $925 million bet on Afrezza--a fast-acting inhaled insulin program that hoped to succeed where Pfizer and Eli Lilly had already thrown in the towel--has run straight into another
Mann doubles down on biotech as Afrezza decision looms
As investors lay down their final bets on the FDA's looming decision on MannKind's Afrezza, the company's wealthy CEO has opted to put his money where his mouth has been--doubling down on an
MannKind shares spike after FDA delays Afrezza decision
One of the biggest decisions on the FDA's calendar this month will have to wait at least a few more weeks. Regulators say they'll need four additional weeks to finalize their decision on MannKind's
FDA accepts Mannkind's response, sets PDUFA date
The FDA has accepted MannKind's resubmission of its NDA for the inhaled insulin drug Afrezza and set a PDUFA action date of December 29, 2010. The much-watched Afrezza NDA received a complete
